HPV infection: Future prospects

Clinics in Dermatology

Volumn 15, Issue 2, 1997, Pages 299-302

  Lowy, Douglas R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CAPSID PROTEIN; HYBRID PROTEIN; VIRUS CAPSID ANTIGEN; VIRUS DNA; VIRUS PROTEIN; VIRUS VACCINE;

ESOPHAGUS CANCER; HOST RESISTANCE; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN CARCINOMA; VIRUS CARCINOGENESIS; VIRUS GENE; VIRUS INFECTION; VIRUS PATHOGENESIS; WART VIRUS;

EID: 0030942671     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(97)00070-9     Document Type: Article

References (33)

1. Kawashima M, Favre M, Obalek S, et al. Premalignant lesions and cancers of the skin in the general population: evaluation of the role of human papillomaviruses. J Invest Derm 1990;95:537-42.
2. Stark L, Arends M, McLaren K, et al. Prevalence of human papillomavirus DNA in cutaneous neoplasms from renal allograft recipients supports a possible viral role in tumour promotion. Br J Cancer 1994;69:222-9.
3. Berkhout RJ, Tieben LM, Smits HL, et al. Nested PCR approach for detection and typing of epidemodysplasia verruciformis-associated human papilomavirus types in cutaneous cancers from renal transplant recipients. J Clin Microbiol 1995;1995:690-5.
4. Shamanin V, zur Hausen H, Lavergne D, et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst 1996;88:802-11.
5. Chang F, Syrjanen S, Shen Q, et al. Screening for human papillomavirus infections in esophageal squamous cell carcinomas by in situ hybridization. Cancer 1993;72:2525-30.
6. Benamouzig R, Jullian E, Chang F, et al. Absence of human papillomavirus DNA detected by polymerase chain reaction in French patients with esophageal carcinoma. Gastroenterology 1995;109:1876-81.
7. Dillner J, Knekt P, Schiller J, et al. Prospective seroepidemiological evidence that human papillomavirus type 16 infection is a risk factor for oesophageal squamous cell carcinoma. BMJ 1995;311:1346.
8. Campo M, O'Neil B, Barron R, et al. Experimental reproduction of the papilloma-carcinoma complex of the alimentary canal in cattle. Carcinogenesis 1994;15:1597-601.
9. Frattini MG, Lim HB, Laimins LA. In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression. Proc Natl Acad Sci U S A 1996;93:3062-7.
10. Christensen N, Cladel N, Reed C, et al. Laboratory production of infectious stocks of rabbit oral papillomavirus. J Gen Virol 1996;77:1793-8.
11. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993;67:315-22.
12. Kirnbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993;67:6929-36.
13. Jansen KU, Rosolowsky M, Schultz LD, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995;13:1509-14.
14. Zhou J, Stenzel DJ, Sun XY, et al. Synthesis and assembly of infectious bovine papillomavirus particles in vitro. J Gen Virol 1993:763-8.
15. Tindle RW, Frazer IH. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. Curr Top Microbiol Immunol 1994;186:218-53.
16. Hampton G, Larson A, Baergen R, et al. Simultaneous assessment of loss of heterozygosity at multiple microsatellite loci using semi-automated fluorescence-based detection: subregional mapping of chromosome 4 in cervical carcinoma. Proc Natl Acad Sci U S A 1996;93:6704-9.
17. Kleine K, Konig G, Kreuzer J, et al. The effect of the JE (MCP-1) gene, which encodes monocyte chemoattractant protein-1, on the growth of HeLa cells and derived somatic-cell hybrids in nude mice. Mol Carcinogenesis 1995; 14:179-89.
18. Han R, Breitburd F, Marche PN, et al. Linkage of regression and malignant conversion of rabbit viral papillomas to MHC class II genes. Nature 1992;356:66-8.
19. Han R, Breitburd F, Marche P, et al. Analysis of the nucleotide sequence variation of the antigen-binding domain of DR alpha and DQ alpha molecules as related to the evolution of papillomavirus-induced warts in rabbits. J Invest Dermatol 1994;103:376-80.
20. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-63.
21. Suzich JA, Ghim S, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995;92:11553-7.
22. Christensen ND, Reed CA, Cladel NM, et al. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996;70:960-5.
23. Kirnbauer R, Chandrachud L, O'Neil B, et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996;219:37-44.
24. Roden RBS, Hubbert NL, Kirnbauer R, et al. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 1996;70: 3298-301.
25. Meneguzzi G, Cerni C, Kieny MP, et al. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia virus expressing E6 and E7. Virology 1991;181:62-9.
26. Chen L, Mizuno MT, Singhal MC, et al. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol. 1992;148:2617-21.
27. Campo MS. Towards vaccines against papillomavirus. In: Stern PL, Stanley MA, editors. Human papillomaviruses and cervical Cancer. Biology and immunology. New York: Oxford University Press, 1994:177-91.
28. Selvakumar R, Borenstein LA, Lin YL, et al. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J. Virol. 1995;69:602-5.
29. Wu TC, Guarnieri FG, Staveley OCKF, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A 1995;92:11671-5.
30. Lin K-Y, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6.
31. Steele C, Cowsert L, Shillitoe E. Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines. Cancer Res 1993;53:2330-7.
32. Thierry F, Yaniv M. The BPV1-E2 transactivating protein can be either an activator or a repressor of the HPV18 regulatory region. EMBO J 1987;6:3391-7.
33. Pan H, Griep A. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev 1994;8:1285-99.